Syndecan-1 (CD138), Carcinomas and EMT
Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/8/4227 |
| _version_ | 1797537123852615680 |
|---|---|
| author | John R. Couchman |
| author_facet | John R. Couchman |
| author_sort | John R. Couchman |
| collection | DOAJ |
| description | Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable of interacting with a large array of polypeptides, including extracellular matrix components and potent mediators of proliferation, adhesion and migration. For this reason, it has been studied extensively with respect to carcinomas and tumor progression. Frequently, but not always, syndecan-1 levels decrease as tumor grade, stage and invasiveness and dedifferentiation increase. This parallels experiments that show depletion of syndecan-1 can be accompanied by loss of cadherin-mediated adhesion. However, in some tumors, levels of syndecan-1 increase, but the characterization of its distribution is relevant. There can be loss of membrane staining, but acquisition of cytoplasmic and/or nuclear staining that is abnormal. Moreover, the appearance of syndecan-1 in the tumor stroma, either associated with its cellular component or the collagenous matrix, is nearly always a sign of poor prognosis. Given its relevance to myeloma progression, syndecan-1-directed antibody—toxin conjugates are being tested in clinical and preclinical trials, and may have future relevance to some carcinomas. |
| first_indexed | 2024-03-10T12:11:32Z |
| format | Article |
| id | doaj.art-6ce603deec2e4d52b3226cc7d6152572 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T12:11:32Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-6ce603deec2e4d52b3226cc7d61525722023-11-21T16:11:55ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01228422710.3390/ijms22084227Syndecan-1 (CD138), Carcinomas and EMTJohn R. Couchman0Biotech Research & Innovation Centre, University of Copenhagen, 2200 Copenhagen, DenmarkCell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable of interacting with a large array of polypeptides, including extracellular matrix components and potent mediators of proliferation, adhesion and migration. For this reason, it has been studied extensively with respect to carcinomas and tumor progression. Frequently, but not always, syndecan-1 levels decrease as tumor grade, stage and invasiveness and dedifferentiation increase. This parallels experiments that show depletion of syndecan-1 can be accompanied by loss of cadherin-mediated adhesion. However, in some tumors, levels of syndecan-1 increase, but the characterization of its distribution is relevant. There can be loss of membrane staining, but acquisition of cytoplasmic and/or nuclear staining that is abnormal. Moreover, the appearance of syndecan-1 in the tumor stroma, either associated with its cellular component or the collagenous matrix, is nearly always a sign of poor prognosis. Given its relevance to myeloma progression, syndecan-1-directed antibody—toxin conjugates are being tested in clinical and preclinical trials, and may have future relevance to some carcinomas.https://www.mdpi.com/1422-0067/22/8/4227proteoglycantumorheparan sulfateglycosaminoglycancadherin |
| spellingShingle | John R. Couchman Syndecan-1 (CD138), Carcinomas and EMT International Journal of Molecular Sciences proteoglycan tumor heparan sulfate glycosaminoglycan cadherin |
| title | Syndecan-1 (CD138), Carcinomas and EMT |
| title_full | Syndecan-1 (CD138), Carcinomas and EMT |
| title_fullStr | Syndecan-1 (CD138), Carcinomas and EMT |
| title_full_unstemmed | Syndecan-1 (CD138), Carcinomas and EMT |
| title_short | Syndecan-1 (CD138), Carcinomas and EMT |
| title_sort | syndecan 1 cd138 carcinomas and emt |
| topic | proteoglycan tumor heparan sulfate glycosaminoglycan cadherin |
| url | https://www.mdpi.com/1422-0067/22/8/4227 |
| work_keys_str_mv | AT johnrcouchman syndecan1cd138carcinomasandemt |